NK Cells in Cancer Immunotherapy: Successes and Challenges: Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy, cartea 4
Editat de Anahid Jewett, Yuman Fongen Limba Engleză Hardback – 8 dec 2022
Immunotherapy is fast becoming the method of choice for cancer therapy. Although remarkable advances have been made in the field of immunotherapy, there are significant challenges and difficulties ahead since many of the current immunotherapeutic strategies do not provide long-lasting treatment strategies, and therefore are not very effective.
- Covers CAR/T and CAR/NK and adoptive NK cell therapy with and without T cell therapies
- Discusses basic biology of NK cells and mouse models of human cancers and the role of NK cells in metastatic cancer and in cancer stem cells
- Encompasses information on combination therapies using check point inhibition, adoptive transfer of cytotoxic effector cells, chemotherapeutic drugs and activating and inhibitory antibodies
Preț: 809.77 lei
Preț vechi: 1052.14 lei
-23% Nou
Puncte Express: 1215
Preț estimativ în valută:
154.96€ • 160.81$ • 129.53£
154.96€ • 160.81$ • 129.53£
Carte indisponibilă temporar
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780128226209
ISBN-10: 012822620X
Pagini: 494
Dimensiuni: 191 x 235 mm
Editura: ELSEVIER SCIENCE
Seria Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
ISBN-10: 012822620X
Pagini: 494
Dimensiuni: 191 x 235 mm
Editura: ELSEVIER SCIENCE
Seria Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
Cuprins
1. Introduction and basic biology of NK cells2. Immunotherapy using CAR/NK with and without CAR/T3. Immunotherapy using NK cells with and without T cells and Tumor infiltrating lymphocytes as well as NK/T cells4. Autologous vs allogeneic sources of NK and T cell effectors5. Reversing NK inhibitory tumor microenvironment by targeting suppressive immune effectors6. Check point inhibitors7. Combination of NK immunotherapy with chemotherapy and radiation8. NK cell immunotherapy using ADCC inducing antibodies9. Oncolytic viruses and NK cell immunotherapy10. NK cell diagnostics11. Novel cell delivery systems